Interleukin-21 is associated with disease activity in patients with Graves' disease

Endocrine

Volumn 46, Issue 3, 2014, Pages 539-548

  Zhang, Jin ^a   Zeng, Hua ^a   Ren, Meng ^a   Yan, Haiyan ^a   Xu, Mingtong ^a   Feng, Zhimei ^a   Liang, Weiwen ^a   Yang, Chuan ^a   Cheng, Hua ^a   Ding, Helin ^a   Yan, Li ^a  

^a SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Graves' disease; Interleukin 21; Thyroid stimulating antibody (TSAb); Thyrotropin receptor antibody (TRAb)

Indexed keywords

ANTITHYROID AGENT; INTERLEUKIN 21; LIOTHYRONINE; THYROGLOBULIN ANTIBODY; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; THYROTROPIN RECEPTOR ANTIBODY; THYROXINE; INTERLEUKIN DERIVATIVE; THYROID STIMULATING IMMUNOGLOBULIN;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; ENDOCRINE OPHTHALMOPATHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FREE LIOTHYRONINE INDEX; GOITER; GRAVES DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PATIENT CODING; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; ADOLESCENT; BLOOD; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; GRAVES DISEASE; HUMANS; IMMUNOGLOBULINS, THYROID-STIMULATING; INTERLEUKINS; MALE; MIDDLE AGED; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE; YOUNG ADULT;

EID: 84904575497     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-013-0105-x     Document Type: Article

References (42)

1. R. Spolski, W.J. Leonard, IL-21 and T follicular helper cells. Int. Immunol. 22(1), 7-12 (2010)
2. R. Liu, Q. Wu, D. Su et al., A regulatory effect of IL-21 on T follicular helper-like cell and B cell in rheumatoid arthritis. Arthr. Res. Ther. 14(6), R255 (2012)
3. R. Spolski, M. Kashyap, C. Robinson et al., IL-21 signaling is critical for the development of type I diabetes in the NOD mouse. Proc. Natl. Acad. Sci. USA 105(37), 14028-14033 (2008)
4. J. Parrish-Novak, S.R. Dillon, A. Nelson et al., Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408(6808), 57-63 (2000)
5. J.M. Coquet, K. Kyparissoudis, D.G. Pellicci et al., IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J. Immunol. 178(5), 2827-2834 (2007)
6. A. Vogelzang, H.M. Mcguire, D. Yu et al., A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity 29(1), 127-137 (2008)
7. B.J. Dien, P. Gelebart, M. Anand et al., IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma. Am. J. Pathol. 175, 825-834 (2009)
8. S. Crotty, Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 29, 621-663 (2011)
9. W.J. Leonard, R. Spolski, Interleukin-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat. Rev. Immunol. 5(9), 688-698 (2005)
10. D. Konforte, N. Simard, C.J. Paige, IL-21: an executor of B cell fate. J. Immunol. 182(4), 1781-1787 (2009)
11. K. Brandt, P.B. Singh, S. Bulfone-Paus et al., Interleukin-21: a new modulator of immunity, infection, and cancer. Cytokine Growth Factor Rev. 18(3-4), 223-232 (2007)
12. S. Dolff, W.H. Abdulahad, J. Westra et al., Increase in IL-21 producing T-cells in patients with systemic lupus erythematosus. Arthr. Res. Ther. 13(5), R157 (2011)
13. J.E. Gottenberg, J.M. Dayer, C. Lukas et al., Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in early rheumatoid arthritis: results from the ESPOIR cohort. Ann. Rheum. Dis. 71 (7), 1243-1248 (2012)
14. R.H. Scofield, IL-21 and Sjogren's syndrome. Arthr. Res. Ther. 13(6), 137 (2011)
15. J.S. Tzartos, M.J. Craner, M.A. Friese et al., IL-21 and IL-21 receptor expression in lymphocytes and neurons in multiple sclerosis brain. Am. J. Pathol. 178(2), 794-802 (2011)
16. A.P. Weetman, Graves' disease. N. Engl. J. Med. 343(17), 1236-1248 (2000)
17. D. Pan, Y.H. Shin, G. Gopalakrishnan et al., Regulatory T cells in Graves' disease. Clin. Endocrinol. (Oxf) 71(4), 587-593 (2009)
18. B. Rapoport, G.D. Chazenbalk, J.C. Jaume et al., The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies. Endocr. Rev. 19(6), 673-716 (1998)
19. B. Rapoport, S.M. Mclachlan, Thyroid autoimmunity. J. Clin. Invest 108(9), 1253-1259 (2001)
20. M.P. Mourits, L. Koornneef, W.M. Wiersinga et al., Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br. J. Ophthalmol. 73(8), 639-644 (1989)
21. W.E. Hinds, N. Takai, B. Rapoport et al., Thyroid-stimulating immunoglobulin bioassay using cultured human thyroid cells. J. Clin. Endocrinol. Metab. 52(6), 1204-1210 (1981)
22. K. Tan, T.P. Loh, S. Sethi, Lack of standardized description of TRAb assays. Endocrine 43(3), 732-733 (2013)
23. Y. Ochi, K. Yamashiro, N. Takasu et al., Sensitive assay to detect thyroid stimulating antibody (TSAb) in the presence of thyroid stimulation blocking antibody (TSBAb) in serum. Horm. Metab. Res. 33(2), 115-120 (2001)
24. H.Y. Jia, Z.G. Zhang, X.J. Gu et al., Association between interleukin 21 and Graves' disease. Genet. Mol. Res. 10(4), 3338-3346 (2011)
25. C. Zhu, J. Ma, Y. Liu et al., Increased frequency of follicular helper T cells in patients with autoimmune thyroid disease. J. Clin. Endocrinol. Metab. 97(3), 943-950 (2012)
26. G. Aust, D. Sittig, L. Becherer et al., The role of CXCR5 and its ligand CXCL13 in the compartmentalization of lymphocytes in thyroids affected by autoimmune thyroid diseases. Eur. J. Endocrinol. 150(2), 225-234 (2004)
27. B.S. Iwona, S.S. Jadwiga, K. Elzbieta et al., Lymphocytes in peripheral blood and thyroid tissue in children with Graves' disease. World J. Pediatr. 4(4), 274-282 (2008)
28. K. Ozaki, R. Spolski, C.G. Feng et al., A critical role for IL-21 in regulating immunoglobulin production. Science 298(5598), 1630-1634 (2002)
29. Y. Abe, Apoptosis in the pathogenesis of autoimmune thyroid disease. Nihon Rinsho 57(8), 1717-1722 (1999)
30. D. Sinclair, Clinical and laboratory aspects of thyroid autoantibodies. Ann. Clin. Biochem. 43(Pt 3), 173-183 (2006)
31. M. Schott, W.B. Minich, H.S. Willenberg et al., Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease. Horm. Metab. Res. 37(12), 741-744 (2005)
32. N. Takasu, M. Matsushita, Changes of TSH-stimulation blocking antibody (TSBAb) and thyroid stimulating antibody (TSAb) over 10 years in 34 TSBAb-positive patients with hypothyroidism and in 98 TSAb-positive Graves' patients with hyperthyroidism: reevaluation of TSBAb and TSAb in TSH-receptor-antibody (TRAb)-positive patients. J. Thyr. Res. 2012, 182176 (2012)
33. B. Rapoport, S. Filetti, N. Takai et al., Studies on the cyclic AMP response to thyroid stimulating immunoglobulin (TSI) and thyrotropin (TSH) in human thyroid cell monolayers. Metabolism 31(11), 1159-1167 (1982)
34. T.K. Rasmussen, T. Andersen, M. Hvid et al., Increased interleukin 21 (IL-21) and IL-23 are associated with increased disease activity and with radiographic status in patients with early rheumatoid arthritis. J. Rheumatol. 37(10), 2014-2020 (2010)
35. M. Rotondi, L. Chiovato, Vitamin D deficiency in patients with Graves' disease: probably something more than a casual association. Endocrine 43(1), 3-5 (2013)
36. T. Yasuda, Y. Okamoto, N. Hamada et al., Serum vitamin D levels are decreased in patients without remission of Graves' disease. Endocrine 43(1), 230-232 (2013)
37. T. Yasuda, Y. Okamoto, N. Hamada et al., Serum vitamin D levels are decreased and associated with thyroid volume in female patients with newly onset Graves' disease. Endocrine 42(3), 739-741 (2012)
38. F. Baeke, T. Takiishi, H. Korf et al., Vitamin D: modulator of the immune system. Curr. Opin. Pharmacol. 10(4), 482-496 (2010)
39. H. Sondergaard, K. Skak, IL-21: roles in immunopathology and cancer therapy. Tissue Antigens 74(6), 467-479 (2009)
40. G. Monteleone, F. Pallone, T.T. Macdonald, Interleukin-21 as a new therapeutic target for immune-mediated diseases. Trends Pharmacol. Sci. 30(8), 441-447 (2009)
41. A.K. Andersson, M. Feldmann, F.M. Brennan, Neutralizing IL-21 and IL-15 inhibits pro-inflammatory cytokine production in rheumatoid arthritis. Scand. J. Immunol. 68(1), 103-111 (2008)
42. J.A. Bubier, S.M. Bennett, T.J. Sproule et al., Treatment of BXSB-Yaa mice with IL-21R-Fc fusion protein minimally attenuates systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 1110, 590-601 (2007)